Multidisciplinary Institute of Oncology, Genolier, Switzerland.
Cancer Treat Rev. 2012 Apr;38(2):120-6. doi: 10.1016/j.ctrv.2011.05.005. Epub 2011 Jul 13.
Oral chemotherapy is one of the options for the treatment of endocrine non-responsive metastatic breast cancer.
A search of the online PubMed database was undertaken to identify clinical trials evaluating oral vinorelbine in metastatic breast cancer. All the clinically relevant data have been analysed in this article.
A total of 31 studies including more than 1000 patients have been included into this analysis. Oral vinorelbine either as a single-agent or in combination has shown consistent efficacy results (response rates between 27% and 85% in first-line). The all-oral combination of oral vinorelbine and capecitabine has shown comparable efficacy to a taxane-based combination in a randomised phase II study. Importantly, activity has also been observed in the subset of patients previously treated with anthracyclines and taxanes. For HER2-positive patients, oral vinorelbine in combination with trastuzumab is among the most active options. Oral vinorelbine presents a manageable tolerance profile. Neutropenia is the most common adverse event and alopecia is not frequently observed. Anti-emetic prophylaxis is recommended.
Taken together, these data indicate that oral vinorelbine is a highly effective and well tolerated agent which can be used in first-line and subsequent metastatic breast cancer settings. Moreover, this compound may offer the specific advantages of oral chemotherapy, as fewer and shorter hospital visits, delayed use of central venous access devices and maintained social activities.
口服化疗是治疗内分泌耐药转移性乳腺癌的选择之一。
检索在线 PubMed 数据库，以确定评估转移性乳腺癌中口服长春瑞滨的临床试验。本文分析了所有临床相关数据。
共有 31 项研究纳入了超过 1000 名患者，结果显示，口服长春瑞滨无论是单药还是联合用药均显示出一致的疗效（一线治疗的缓解率为 27%至 85%）。在一项随机 II 期研究中，口服长春瑞滨和卡培他滨的全口服联合与紫杉类药物联合具有相当的疗效。重要的是，在先前接受过蒽环类药物和紫杉类药物治疗的患者亚组中也观察到了活性。对于 HER2 阳性患者，长春瑞滨联合曲妥珠单抗是最有效的选择之一。口服长春瑞滨具有可管理的耐受性。最常见的不良反应是中性粒细胞减少，且通常不会出现脱发。建议进行止吐预防。
综上所述，这些数据表明，口服长春瑞滨是一种高效且耐受性良好的药物，可用于一线和后续转移性乳腺癌治疗。此外，这种药物可能具有口服化疗的特定优势，如减少和缩短住院次数、延迟使用中央静脉置管和维持社交活动。
